What do systematic reviews say?

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.33 [0.33, 5.45]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.56 [0.24, 10.05]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.23 [0.35, 4.4]
  2 studies · 144 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 66 participants
  Low

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 76 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 110 participants
  Low

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 110 participants
  Moderate

TDF vs AZT

TDF showed no clear difference in serious adverse events compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 0.92 [0.6, 1.43]
  2 studies · 586 participants
  High

TDF vs AZT

TDF showed no clear difference in virologic response compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 2.04 [0.17, 24.84]
  2 studies · 586 participants
  High

TDF vs AZT

TDF probably leads to higher adherence/tolerability/retention compared with AZT (moderate certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 1.17 [1.06, 1.29]
  2 studies · 586 participants
  Moderate

TDF vs AZT

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 515 participants
  Moderate

TDF vs AZT

It is very uncertain whether TDF changes drug resistance compared with AZT (very low certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 20.43 [1.24, 335.9]
  1 study · 71 participants
  Very low